Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Operating Income (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Operating Income data on record, last reported at -$23.1 million in Q4 2025.

  • For Q4 2025, Operating Income rose 38.62% year-over-year to -$23.1 million; the TTM value through Dec 2025 reached -$115.2 million, up 3.67%, while the annual FY2025 figure was -$115.2 million, 3.67% up from the prior year.
  • Operating Income reached -$23.1 million in Q4 2025 per CCCC's latest filing, up from -$34.4 million in the prior quarter.
  • Across five years, Operating Income topped out at -$15.3 million in Q4 2021 and bottomed at -$38.3 million in Q4 2022.
  • Average Operating Income over 5 years is -$29.3 million, with a median of -$28.8 million recorded in 2025.
  • Peak YoY movement for Operating Income: crashed 151.02% in 2022, then surged 42.92% in 2024.
  • A 5-year view of Operating Income shows it stood at -$15.3 million in 2021, then plummeted by 151.02% to -$38.3 million in 2022, then increased by 2.26% to -$37.4 million in 2023, then decreased by 0.75% to -$37.7 million in 2024, then soared by 38.62% to -$23.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$23.1 million in Q4 2025, -$34.4 million in Q3 2025, and -$28.5 million in Q2 2025.